Malignant Neoplasms
BeiGene Rebrands as BeOne Medicines, Emphasizing Global Unity Against Cancer
BeiGene, BeOne Medicines, Global Oncology, Cancer Treatment, Name Change, Strategic Growth
FDA Delays Decision on Merus’ Zenocutuzumab for NRG1+ Lung and Pancreatic Cancer
Zenocutuzumab, NRG1+ cancer, FDA delay, Merus, lung cancer, pancreatic cancer, bispecific antibody.
Crescent Biopharma’s Public Debut Fueled by PD-1/VEGF Combination Therapy Enthusiasm
PD-1/PD-L1 inhibitors, VEGF inhibitors, Combination therapy, Cancer treatment, Biopharmaceutical industry, Public listing
Sanofi Invests €300M in Orano Med for Next-Generation Radioligand Therapies
Sanofi, Orano Med, Radioligand Therapies, Rare Cancers, AlphaMedix, Lead-212 (212Pb), Targeted Alpha Therapies
Ono Pharmaceutical Partners with LigaChem Biosciences for ADC Research and Development
Ono Pharmaceutical, LigaChem Biosciences, Antibody-Drug Conjugate (ADC), LCB97, ConjuAll ADC platform, Solid Tumors, Cancer Treatment
Aptadir Therapeutics Unveils Novel RNA Inhibitors to Combat Cancer and Genetic Disorders
Aptadir Therapeutics, RNA inhibitors, DNMT1 interacting RNAs (DiRs), Cancer treatment, Genetic diseases, Epigenetic targeting, RNA therapeutics
ITM Secures Exclusive Global License for Debiopharm’s CA IX-Targeted Theranostic Pair
ITM, Debiopharm, CA IX, Theranostic Pair, Radiopharmaceutical, Solid Tumors, Cancer Treatment
PanTera Secures €93M to Tackle Alpha-Emitter Isotope Shortage Amid Growing Demand
Alpha-emitters, Isotope shortage, PanTera, Cancer treatment, Radiation therapy
Duality Biotherapeutics Files for Hong Kong IPO, Expanding ADC Therapeutics Portfolio
Duality Biotherapeutics, Hong Kong IPO, ADC Therapeutics, BioNTech, BeiGene, Cancer Treatment
Merck & Co. Expands Oncology Pipeline with Kelun-Biotech ADCs
Merck & Co., Kelun-Biotech, Antibody-Drug Conjugates (ADCs), Cancer Treatment, Oncology Pipeline